Show simple item record

dc.contributor.authorPallebage-Gamarallage, M
dc.contributor.authorFoxley, S
dc.contributor.authorMenke, RAL
dc.contributor.authorHuszar, IN
dc.contributor.authorJenkinson, M
dc.contributor.authorTendler, BC
dc.contributor.authorWang, C
dc.contributor.authorJbabdi, S
dc.contributor.authorTurner, MR
dc.contributor.authorMiller, KL
dc.contributor.authorAnsorge, O
dc.date.accessioned2020-12-10T00:26:42Z
dc.date.available2020-12-10T00:26:42Z
dc.date.issued2018-03-13
dc.identifierpii: 10.1186/s12868-018-0416-1
dc.identifier.citationPallebage-Gamarallage, M., Foxley, S., Menke, R. A. L., Huszar, I. N., Jenkinson, M., Tendler, B. C., Wang, C., Jbabdi, S., Turner, M. R., Miller, K. L. & Ansorge, O. (2018). Dissecting the pathobiology of altered MRI signal in amyotrophic lateral sclerosis: A post mortem whole brain sampling strategy for the integration of ultra-high-field MRI and quantitative neuropathology.. BMC Neurosci, 19 (1), pp.11-. https://doi.org/10.1186/s12868-018-0416-1.
dc.identifier.issn1471-2202
dc.identifier.urihttp://hdl.handle.net/11343/253491
dc.description.abstractBACKGROUND: Amyotrophic lateral sclerosis (ALS) is a clinically and histopathologically heterogeneous neurodegenerative disorder, in which therapy is hindered by the rapid progression of disease and lack of biomarkers. Magnetic resonance imaging (MRI) has demonstrated its potential for detecting the pathological signature and tracking disease progression in ALS. However, the microstructural and molecular pathological substrate is poorly understood and generally defined histologically. One route to understanding and validating the pathophysiological correlates of MRI signal changes in ALS is to directly compare MRI to histology in post mortem human brains. RESULTS: The article delineates a universal whole brain sampling strategy of pathologically relevant grey matter (cortical and subcortical) and white matter tracts of interest suitable for histological evaluation and direct correlation with MRI. A standardised systematic sampling strategy that was compatible with co-registration of images across modalities was established for regions representing phosphorylated 43-kDa TAR DNA-binding protein (pTDP-43) patterns that were topographically recognisable with defined neuroanatomical landmarks. Moreover, tractography-guided sampling facilitated accurate delineation of white matter tracts of interest. A digital photography pipeline at various stages of sampling and histological processing was established to account for structural deformations that might impact alignment and registration of histological images to MRI volumes. Combined with quantitative digital histology image analysis, the proposed sampling strategy is suitable for routine implementation in a high-throughput manner for acquisition of large-scale histology datasets. Proof of concept was determined in the spinal cord of an ALS patient where multiple MRI modalities (T1, T2, FA and MD) demonstrated sensitivity to axonal degeneration and associated heightened inflammatory changes in the lateral corticospinal tract. Furthermore, qualitative comparison of R2* and susceptibility maps in the motor cortex of 2 ALS patients demonstrated varying degrees of hyperintense signal changes compared to a control. Upon histological evaluation of the same region, intensity of signal changes in both modalities appeared to correspond primarily to the degree of microglial activation. CONCLUSION: The proposed post mortem whole brain sampling methodology enables the accurate intraindividual study of pathological propagation and comparison with quantitative MRI data, to more fully understand the relationship of imaging signal changes with underlying pathophysiology in ALS.
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.titleDissecting the pathobiology of altered MRI signal in amyotrophic lateral sclerosis: A post mortem whole brain sampling strategy for the integration of ultra-high-field MRI and quantitative neuropathology.
dc.typeJournal Article
dc.identifier.doi10.1186/s12868-018-0416-1
melbourne.affiliation.departmentCentre for Neuroscience
melbourne.source.titleBMC Neuroscience
melbourne.source.volume19
melbourne.source.issue1
melbourne.source.pages11-
dc.rights.licenseCC BY
melbourne.elementsid1318134
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848544
melbourne.contributor.authorJenkinson, Mark
dc.identifier.eissn1471-2202
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record